- Documentinforme (1)uploaded by
alvaro.bosch.ibanez
- Documentinformeuploaded by
alvaro.bosch.ibanez
- Documentjamaneurology_mendell_2021_oi_210023_1624467431.00495uploaded by
alvaro.bosch.ibanez
- Documentinforme (2)uploaded by
alvaro.bosch.ibanez
- DocumentAtrofia_muscular_espinaluploaded by
alvaro.bosch.ibanez
- DocumentGil Lizarraga, Uxueuploaded by
alvaro.bosch.ibanez
- DocumentSpinal Muscular Atrophyuploaded by
alvaro.bosch.ibanez
- DocumentSafety and efficacy of nusinersen in spinal muscular atrophy The EMBRACE studyuploaded by
alvaro.bosch.ibanez
- DocumentSpinal muscular atrophy From approved therapies to future therapeutic targets for personalized medicineuploaded by
alvaro.bosch.ibanez
- DocumentNew and Developing Therapies in Spinal Muscularuploaded by
alvaro.bosch.ibanez
- DocumentExpert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophyuploaded by
alvaro.bosch.ibanez
- DocumentFive-Year Extension Results of the Phase 1 START Trialuploaded by
alvaro.bosch.ibanez
- DocumentAdvances and limitations for the treatment of spinal muscular atrophyuploaded by
alvaro.bosch.ibanez